Our venture capital fund focuses investments on early-stage life sciences companies looking to improve people’s outcomes with cancer.

Recent News

C4-logo-wht
01/04/2024

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

READ MORE
wugen-logo-400
01/03/2024

Wugen Strengthens Executive Leadership Team with Appointment of Keith Vendola, M.D., M.B.A. as Chief Financial Officer

READ MORE
C4-logo-wht
12/12/2023

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

READ MORE
C4-logo-wht
12/12/2023

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

READ MORE
wugen-logo-400
12/11/2023

Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting

READ MORE
CareVet-Logo-New
12/05/2023

CareVet Attains Mansfield Certification Plus, Demonstrating Commitment to Diversity and Inclusion

READ MORE
Logo-Geneoscopy-400
12/05/2023

Geneoscopy and Adiso Therapeutics Announce Strategic Collaboration to Investigate New Therapeutic Options for Patients with Inflammatory Bowel Disease

READ MORE
wugen-logo-400
12/03/2023

WUCART7 1001 Phase 1/2 Dose-Escalation/Dose-Expansion Study

READ MORE
C4-logo-wht
11/28/2023

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

READ MORE

PORTFOLIO HIGHLIGHTS

WUGEN Logo
White C4 Therapeutics logo
Geneoscopy logo
NextRNA Logo
CareVet Logo
microbial-logo-header300